BCL2 and small cell lung carcinoma: Importantly, each subtype exhibits differential therapeutic responses: SCLC-I responds well to immunotherapy (particularly when combined with chemotherapy) due to its high expression of inflammation-related and immune checkpoint genes; SCLC-P shows particular sensitivity to PARP inhibitors; SCLC-N demonstrates good response to Aurora kinase inhibitors; and SCLC-A exhibits sensitivity to BCL-2 inhibitors.